Rhenman & Partners Asset Management Ab Cassava Sciences Inc Transaction History

Rhenman & Partners Asset Management Ab

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$36.77 - $90.91 $3.13 Million - $7.73 Million	-85,000 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$41.79 - $135.3 $1.25 Million - $4.06 Million	-30,000 Reduced 26.09%	85,000 $5.28 Million
Q2 2021 Aug 13, 2021	BUY	$32.15 - $89.72 $3.7 Million - $10.3 Million	115,000 New	115,000 $9.83 Million

172

11.3M

1.61M

1.43M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $473M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.